|
rs980171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three adjacent SNPs centromeric to prostate cancer risk-region 2 (rs12334903, rs1456310, and rs980171) were associated with testosterone (P < 1.1 x 10(-3)) and bioavailable testosterone (P < 6.3 x 10(-4)).
|
20551303 |
2010 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC.
|
22067658 |
2011 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
SNP rs16901979 in region 2 was associated with significantly increased risk of prostate cancer (OR = 1.41, 95% confidence interval [CI] 1.02-1.95, P = 0.04) with the risk stronger in men with early-onset prostate cancer (OR = 2.37, 95% CI 1.40-3.99, P = 0.001).
|
21557270 |
2011 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC.
|
22067658 |
2011 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
There was a tendency towards significantly increased risk for SNPs rs1447295 and rs6983267 in men with early-onset prostate cancer.
|
21557270 |
2011 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Correlation between genotypes and biopsy outcome (positive or negative) and Gleason score (≤6 or >6) were studied by univariate and multivariable analysis. rs1447295 and rs6983267 risk variants were found to be associated with the presence of PCa in univariate analysis. rs6983267 genotype remained significantly linked to a positive biopsy (odds ratio [OR] = 1.66, 95% confidence interval [CI]: 1.06-2.59, P = 0.026) in multivariable analysis, but rs1447295 genotype did not (OR = 1.47, 95% CI: 0.89-2.43, P = 0.13).When biopsy outcome was stratified according to Gleason score, risk variants of rs1447295 were associated with aggressive disease (Gleason score ≥7) in univariate and multivariable analysis (OR = 2.05 95% CI: 1.10-3.79, P = 0.023). rs6983267 GG genotype was not related to aggressiveness.
|
21308149 |
2011 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A highly significant association (odds ratio=2.84 and p-value=0.002) was found between rs6983267 and prostate cancer in the Greek population.
|
22070222 |
2011 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
In the Japanese population examined in this study, the rs6983561 polymorphism at 8q24 was significantly associated with prostate cancer mortality, especially among patients with metastatic disease.
|
21700508 |
2011 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Furthermore, the SNPs rs6983561 and rs4430796 were associated with a susceptibility to aggressive prostate cancer, whereas rs1859962 was associated with non-aggressive prostate cancer.
|
21557267 |
2011 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
We found nominal evidence (P < 0.05) for association between prostate cancer and three chromosome 8q24 (rs6983561, rs16901979, and rs7000448) and two 10q11 (rs7904463 and rs10740051) SNPs.
|
20717903 |
2011 |
|
rs1456315
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Here, focusing on its most centromeric region (so-called Region 2: Chr8: 128.14-128.28 Mb) among the multiple PC loci on 8q24, we performed fine mapping and re-sequencing of this critical region and identified SNPs (single nucleotide polymorphisms) between rs1456315 and rs7463708 (chr8: 128,173,119-128,173,237 bp) to be most significantly associated with PC susceptibility (P = 2.00 × 10(-24) , OR = 1.74, 95% confidence interval = 1.56-1.93).
|
20874843 |
2011 |
|
rs620861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This approach identified rs378854, which is in complete linkage disequilibrium (LD) with rs620861, as a novel functional prostate cancer-specific genetic variant.
|
21814516 |
2011 |
|
rs378854
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This approach identified rs378854, which is in complete linkage disequilibrium (LD) with rs620861, as a novel functional prostate cancer-specific genetic variant.
|
21814516 |
2011 |
|
rs7463708
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, focusing on its most centromeric region (so-called Region 2: Chr8: 128.14-128.28 Mb) among the multiple PC loci on 8q24, we performed fine mapping and re-sequencing of this critical region and identified SNPs (single nucleotide polymorphisms) between rs1456315 and rs7463708 (chr8: 128,173,119-128,173,237 bp) to be most significantly associated with PC susceptibility (P = 2.00 × 10(-24) , OR = 1.74, 95% confidence interval = 1.56-1.93).
|
20874843 |
2011 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In conclusion, this is the first study showing that prostate cancer risk variants, such as rs16901979, might improve outcome prediction following ADT, thus allowing identification of high-risk patients who might benefit from appropriate adjuvant therapy.
|
21445969 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rs16901979 CA genotype carriers had a higher risk of prostate cancer than the CC genotype.
|
22583965 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
SNPs rs6983561, rs7008482, and rs16901979 were significantly associated with CaP risk in WAs (P < 0.03).
|
22234922 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not.
|
22382457 |
2012 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not.
|
22382457 |
2012 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Early-onset marker rs6983561 adds potentially useful clinical information for African American men undergoing prostate cancer risk assessment.
|
22144497 |
2012 |
|
rs13254738
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not.
|
22382457 |
2012 |
|
rs16901966
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Four of the 14 single nucleotide polymorphisms were associated with prostate cancer risk, including rs16901966 (OR 1.343, 95% CI 1.029-1.754, p = 0.030), rs1447295 (OR 1.499, 95% CI 1.109-2.027, p = 0.008), rs11986220 (OR 1.589, 95% CI 1.160-2.178, p = 0.004) and rs10090154 (OR 1.571, 95% CI 1.146-2.154, p = 0.005).
|
22099997 |
2012 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Significant associations were observed for rs4430796 TT with Gleason scores of ≥ 7 (OR = 1.76, 95% CI = 1.14-2.73) and prostate-specific antigen (PSA) levels of ≥ 10 ng/ml at diagnosis (OR = 1.63, 95% CI = 1.01-2.63), as well as for rs6983267 GG with stage 3-4 CaPs (OR = 1.91, 95% CI = 1.01-3.61).
|
22561070 |
2013 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These included correlations between an intergenic CpG site at Chr8:128393157 and the prostate cancer SNP rs16902094 (ρ = -0.54; P = 9.7 × 10(-7); q = 0.002), a PRNCR1 CpG site at Chr8:128167809 and the prostate cancer SNP rs1456315 (ρ = 0.52; P = 1.4 × 10(-6); q = 0.002), and two POU5F1B CpG sites and several prostate/colorectal cancer SNPs (for Chr8:128498051 and rs6983267, ρ = 0.46; P = 2.0 × 10(-5); q = 0.01).
|
25315430 |
2014 |
|
rs6983267
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The polymorphism rs6983267 from region 3 of the chromosome 8q24 appears to be a prominent risk factor for PCa and a biomarker for cancer aggressiveness in the group of patients who presented higher levels of PSA at the time of diagnosis.
|
24224612 |
2014 |